A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)

Inclusion Criteria: * Signed informed consent * Age ≥ 18 years * Histologically confirmed CRC with evidence of metastases and measurable tumor lesions * Documented disease progression following, or intolerance to, treatment with 5-fluorouracil, oxaliplatin, and bevacizumab-based therapy * Life expectancy \> 3 months * For patients of reproductive potential (males and females), use of reliable means for contraception (e.g., contraceptive pill, intrauterine device \[IUD\], physical barrier) throughout the trial and for 6 months following their final exposure to study treatment * Willingness and capability to be accessible for study follow-up Exclusion Criteria: * Patients who have a Kras mutation will be excluded from receiving cetuximab-containing regimens * Prior radiotherapy to a measurable metastatic lesion(s) to be used for response assessment, unless the lesion has progressed subsequent to the radiotherapy * Recent radiotherapy to a peripheral lesion, thoracic, abdominal, or pelvic field * Recent chemotherapy, hormonal therapy, or immunotherapy * Evidence of clinically detectable ascites * Other invasive malignancies within 5 years * History or evidence of active central nervous system (CNS) disease * Current or recent participation in another experimental drug study * Clinically significant cardiovascular disease * Active infection requiring parenteral antibiotics * Recent major surgical procedure, open biopsy, significant traumatic injury, fine needle aspirations, or anticipation of need for major surgical procedure during the course of the study * Known or suspected to be positive for the human immunodeficiency virus (HIV) * Known to be positive for hepatitis C or hepatitis B surface antigen * History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or specified study treatment * Pregnancy (positive pregnancy test) or breast feeding * Serious, non-healing wound, ulcer, or bone fracture * Known sensitivity to any of the products administered during the study * Any disorder that compromises the ability of the patient to provide written informed consent and/or comply with study procedures